SALT LAKE CITY, Nov. 20, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of an AI-powered version of BluePrint Protect™ from Intraprise Health, LLC ("Intraprise Health"), a platform that empowers healthcare organizations to screen and identify risks related to cybersecurity threats through third parties.
On... Read more
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs
Platform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discovery
Recursion will host an update call today, November 20, 2024 at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m.... Read more
CRM Bot and Voice Control deliver GenAI-powered assistance in Vault CRM MADRID and PLEASANTON, Calif., Nov. 20, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Vault CRM Bot and Vault CRM Voice Control, two new GenAI capabilities in Vault CRM. Unveiled at Veeva Commercial Summit Europe, CRM Bot and Voice Control join a host of new innovations coming to Vault CRM next year. With these new capabilities, companies can deploy AI that will have... Read more
MONTRÉAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian health tech company, announces that it successfully deployed AI at its two subsidiaries to meet its digital transformation, efficiency and sustainability objectives.
Premier Health has deployed AI capabilities at its two Quebec per diem subsidiaries, Premier Soin and Code Bleu. The AI’s maturity has achieved a remarkable... Read more
Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter
Strengthened payer coverage highlighted by securing the two remaining large Medicare contracts; broad commercial and Medicare coverage now extends to more than 80% of covered lives
New XDEMVY data demonstrated statistically significant and clinically meaningful improvements from baseline across objective measures of Meibomian Gland Disease... Read more
Innovative Antibodies Show Promise for Antibody-Drug Conjugate (ADC) Development, Paving the Way for Transformative Cancer Treatments VICTORIA, British Columbia / Nov 13, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven medical innovation, is proud to announce a significant breakthrough in its primary cancer research initiatives. This accomplishment not only highlights IPA’s cutting-edge discovery... Read more
Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia.
The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. Recursion expects to host an update call after the anticipated close on... Read more
SALT LAKE CITY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today the release of OpenPhenom-S/16, a publicly available foundation model in Google Cloud’s Vertex AI Model Garden. This will enable Life Science companies to use OpenPhenom-S/16 on Google Cloud when building apps that require microscopy data to assess the effectiveness of drug treatments, analyze... Read more
Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first patient dosed for a Phase 2 trial in recurrent C. difficile infection, and IND clearance for a Phase 1/2 trial in biomarker-enriched solid tumors and lymphoma (Target RBM39), which highlight a growing number of potential clinical program catalysts
Our first neuroscience phenomap was optioned by Roche-Genentech for $30 million as part of... Read more
HEALWELL's AI and data science subsidiaries have executed 5 new Master Services Agreements ("MSA") with new pharmaceutical partners in Q3-2024; bringing the total number of MSAs with life sciences partners to 27, which includes 6 of the top 10 pharmaceutical companies in the world. HEALWELL's AI and data science subsidiaries generated patient identification revenue from 23 of these pharmaceutical partners in Q3-2024.
HEALWELL subsidiary, Khure Health, has executed an... Read more
Rabbit B Cell Select® Platform Yields Novel Antibodies for Studying Age-Related Mitochondrial Dysfunction VICTORIA, British Columbia / Oct 28, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces its significant contribution to a groundbreaking study. The research, led by top scientists at the Mayo Clinic, was initially published in bioRxiv and subsequently... Read more
VANCOUVER, British Columbia, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies announced today that it has received initial results from the proprietary Deep Docking AI platform.
Rakovina employed the Deep Docking algorithm to evaluate billions of molecular structures to develop a short-list of drug candidates that have been... Read more
Enables transcription of handwritten test request forms to digitized format
Utilizes innovative AI for higher accuracy and efficiency
Data is securely processed with ISO27001 compliant solution WALTHAM, Mass. / Oct 22, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced the launch of Revvity Transcribe AI, an innovative optical character recognition (OCR) service designed to convert handwritten text on test request forms into a digitized format. This... Read more
REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS.
REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin's innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract.
There are up to 175,000 cases of recurrent C. diff. each year and more than 29,000 patients die in the U.S. from C. diff. annually. Rates... Read more
Application goes beyond data aggregation to help clinicians quickly see a longitudinal view of their patient’s history, spotlighting disease progression and helping to inform proactive interventions
Tampa General Hospital and UT Southwestern Medical Center to be early evaluators of CareIntellect for Oncology
Application is the first within GE HealthCare’s new CareIntellect offering of clinical and operational applications, built to reduce provider integration burden... Read more
Innovations include Health Companion research project powered by agentic AI
Additional early innovations explore pressing care needs, including identifying new ways to detect breast cancer and improving quality of care for moms and babies CHICAGO / Oct 21, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC) today announced a new AI Innovation Lab, an initiative designed to accelerate early-concept AI innovations within the company. These projects are one part of GE... Read more
DRAPER, Utah, Oct. 15, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (Nasdaq: HQY) ("HealthEquity") in celebration of National HSA Awareness Day, has launched HSAnswers. Powered by a comprehensive and bespoke database of resources, research, and insights, the free-to-use AI chat tool can help individuals obtain clear answers to questions about HSAs and other consumer-directed benefits.
In 2024 HealthEquity surveyed over 600 employees who said their top benefits challenge... Read more
Integrated feature from Blackford offers AI-enabled decision support to help radiologists adapt to higher workloads and increased exam complexity CHICAGO / Oct 09, 2024 / Business Wire / GE HealthCare integrates third party artificial intelligence (AI)-enabled application orchestration feature into True PACS and Centricity PACS. 1 In collaboration with Blackford, the new AI-enabled offerings help radiologists with their workload which could help lead to quicker diagnosis... Read more
Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets
Strongest outcomes are generated by the top-ranked AI-Immunology™ vaccine targets, thereby linking AI-vaccine design with real-world evidence
This underscores the platform’s unique potential in selecting effective vaccine targets
The ongoing generation of relevant clinical data allows for continuous refinement of... Read more
OntarioMD's independent study of AI scribes, which included WELL's AI Voice solution and several others, found over a 70% reduction in time spent on patient encounter documentation, allowing physicians more time for patient care.
82.3% of primary care providers expressed a desire to continue using AI scribes long-term due to improvements in workflow efficiency and reduced after-hours documentation.
The study revealed an average decrease of 3.5-minute reduction in time... Read more
KCU incorporates Butterfly Network's AI-guided ScanLab™ education application into its curriculum to empower dedicated, hands-on ultrasound training. KANSAS CITY, Mo. and BURLINGTON, Mass., Oct. 8, 2024 /PRNewswire/ -- Kansas City University (KCU) is revolutionizing medical education by becoming a leader in point-of-care ultrasound (POCUS) training. In collaboration with Butterfly Network, Inc. ("Butterfly") (NYSE: BFLY), KCU transformed its POCUS... Read more
AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures
Host-directed antiviral drugs have the potential to enhance the immune response to viruses from a range of viral families
Tonix was awarded a contract with the U.S. Department of Defense for up to $34 million for the accelerated development of its host-directed... Read more
CHS and Denim Health are working together to enhance patient experience and generate efficiencies across CHS’ proprietary call center that serves approximately 1,000 primary care providers FRANKLIN, Tenn. & AUSTIN, Texas / Oct 07, 2024 / Business Wire / Community Health Systems, Inc. (NYSE: CYH) (“CHS”) and Denim Health have announced a development partnership that is aimed at revolutionizing the call center experience for patients through the implementation... Read more
Ainos pioneers AI-powered digital nose technology with VOC detection breakthroughs for early disease diagnosis, industrial safety, and human-like sensory capabilities in robots
VELDONA® low-dose oral interferon technology demonstrates huge potential in in viral, autoimmune, and veterinary treatments SAN DIEGO, CA / ACCESSWIRE / October 7, 2024 / Ainos, Inc. (NASDAQ:AIMD) (NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced... Read more
TC BioPharm Limited is partnering with Dr. Wei Wu of Carnegie Mellon University to create an artificial intelligence solution to optimize the donor screening and matching process
The software could have additional applications across cell therapy for donor/patient matching EDINBURGH, Scotland, Oct. 3, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic... Read more
RESEARCH TRIANGLE PARK, N.C. / Oct 02, 2024 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today introduces IQVIA AI Assistant, a generative AI technology that enables a step-change enhancement in how life science customers receive timely and powerful insights.
IQVIA AI Assistant is a user-friendly, conversational text interface that... Read more
Logica®, an offering from Charles River and Valo Health, will be leveraged to progress Lundbeck’s research into disorders of the central nervous system WILMINGTON, Mass. / Oct 02, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement with H. Lundbeck A/S (Lundbeck) to utilize Logica® to progress critical brain disease research.
“We are excited to partner with Lundbeck as they work toward the discovery of... Read more
First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months
Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including patients with solid tumors and lymphoma SALT LAKE CITY, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology... Read more
Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipeline
Highlights InstaDeep’s new near exascale supercomputer, Kyber, with the aim of enabling BioNTech to compute at scale
Unveils novel AI Bayesian Flow Network (“BFN”) models for protein sequence generation
Highlights progress in deploying AI across BioNTech’s immunotherapy pipeline, including in immunohistochemistry, DNA/RNA sequencing, proteomics, protein... Read more
Leading health systems and providers experience increased productivity, revenue, and satisfaction with AI adoption
75% report positive ROI from AI in healthcare payments; 90% plan to boost AI investments in the near future LEHI, Utah and LOUISVILLE, Ky., Sept. 24, 2024 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, and Modern Healthcare today announced new research that reveals how artificial intelligence (AI)... Read more
HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real time* REDWOOD CITY, Calif., Sept. 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the U.S. Food and Drug Adm... Read more
AMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube’s AI-driven, multi-omic platform for early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving... Read more
First Unfold AI®-Assisted Focal One procedures successfully performed at the UCLA School of Medicine
FDA-cleared Unfold AI enables urologists to provide tailored, patient-specific Robotic HIFU ablation for prostate cancer patients
EDAP and Avenda Health to present Unfold AI-Assisted Focal One simulated procedures at the 2024 Joint Meeting of the Focal Therapy Society & Society of Urologic Robotic Surgeons in Washington, DC September 19-21, 2024 LYON, France,... Read more
11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate
15 out of the 16 patients had a reduction of their tumors (target lesions)
79% of EVX-01’s vaccine targets triggered a targeted immune response, which compares very favorably to what is seen with other approaches
A positive correlation was observed between the AI-Immunology™ platform predictions and neoantigen immune response (p=0.00013)
EVX-01 as a novel potential melanoma... Read more
CHICAGO / Sep 12, 2024 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower individuals to holistically organize, manage, and proactively take control of their own health data. olivia, which is currently only available to beta users, leverages generative AI to provide... Read more
Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions
Progressing with proven path toward standard of care addressing chronic low back pain, the largest expenditure in US healthcare costing Americans an estimated $134 Billion annually
More than $50 Million has been invested in the promising Aclarion AI platform that aids physicians in identification of painful discs
Technology protected by... Read more
Collaboration will enhance existing QSight capabilities and enable future platform and service innovations to help optimize complex inventory management for hospitals and health systems RICHMOND, Va. / Sep 10, 2024 / Business Wire / Owens & Minor, Inc. today announced a new partnership with Google Cloud that combines Owens & Minor’s deep expertise in optimizing the healthcare supply chain with Google Cloud’s Vertex AI platform to help drive meaningful enhancements... Read more
The availability of Micro-Neighborhood® Targeting on the Company’s Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing
OptimizeRx presents panel session at Digital Pharma East: Unlocking Opportunity through HCP+DTC Alignment in Omnichannel Oncology Marketing WALTHAM, Ma., Sept. 09, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of... Read more
The Roche Digital Pathology Open Environment brings together a wide array of innovative AI-based pathology tools to help clinicians improve patient care and expand personalised healthcare.
Roche is now integrating more than 20 artificial intelligence (AI) algorithms from eight new collaborators into its digital pathology open environment.
AI technology helps enhance pathology with high value insights, which can benefit cancer patients through precision medicine leading... Read more
